



CEO's message regarding the subscription program of options, the TO 1 series

Dear colleagues, dear investors!

Microorganisms resistant to antibiotics are considered a growing global threat that no one has so far been able to stop. Under the pandemic's shadow many have forgotten that our modern healthcare and meat production completely depend on antibiotics. 700,000 people die annually from antibiotic-resistant bacteria and by 2050, the WHO estimates that 10 million will die annually. The overuse of antibiotics is the cause of the resistance. Antibiotics should be used properly and only when necessary. The WHO has reported that innovative antibiotics will cost additional large investments, which may lead to even fewer antibacterial drugs reaching the market. There is, therefore, an extremely great need for novel approaches to combating the spread of infectious diseases.

FarmPharma has found a smart and unique solution that will be able to treat viral diseases in both sick and healthy animals, reduce overuse of antibiotics and the development of antibiotic resistance. Our unique solution is based on bioactive substances – interferons, which increase the resistance to infections by strengthening the body's immune system.

Three months ago, the development of our products in a lab environment began by collaboration with Karolinska Institute and institutions in Moscow, so we have access to the best scientific expertise in both East and West. We have created an international consortium and, as a EUROSTAR project, received funding for the development of our first product - InterferOx. We are focused on developing our first product - InterferOx to treat cattle. In the next step we will scale up the platform to other animal species.



CEO's message regarding the subscription program of options, the TO 1 series

Every part of the pharmaceutical industry leaves its mark on the environment – from society, patient and distribution – to development. We work strategically to achieve the absolute least potential impact on the environment. Through our active community involvement and sustainable business, we can create a long-term perspective that generates sustainable profits for both owners and society. The board and management see enormous potential in FarmPharma, and the goal is to list the company during 2022.

As the threat of resistant bacteria grows, the world authorities will set aside gigantic resources for novel approaches to combat the spread of infectious diseases. FarmPharma's products can be the piece of the puzzle needed to revolutionize the industry and therefore I would like to invite you to draw options.

Terms for the TO 1 series warrant:

The subscription price is SEK 2.00 per share. Subscription will be possible during the period October 6, 2021, through October 20, 2021.

Greetings,
Dr. Irina Zaitseva,
CEO